



Humanwissenschaftliche Fakultät

Marcel Konrad | Jens Bohlken | Michael A. Rapp | Karel Kostev

# Depression Risk in Patients with Heart Failure in Primary Care Practices in Germany

Suggested citation referring to the original publication:  
International Psychogeriatrics Vol. 28, No. 11 (2016)  
DOI <http://dx.doi.org/10.1017/S1041610216000867>  
ISSN (print) 1041-6102  
ISSN (online) 1741-203X

Postprint archived at the Institutional Repository of the Potsdam University in:  
Postprints der Universität Potsdam  
Humanwissenschaftliche Reihe ; 458  
ISSN 1866-8364  
<http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-414159>



# Depression risk in patients with heart failure in primary care practices in Germany

Marcel Konrad,<sup>1</sup> Jens Bohlken,<sup>2</sup> Michael A Rapp<sup>3</sup> and Karel Kostev<sup>4</sup>

<sup>1</sup>Fresenius University of Applied Sciences, Idstein, Germany

<sup>2</sup>Psychiatric Practice Bohlken, Berlin, Germany

<sup>3</sup>Department of Social and Preventive Medicine, University of Potsdam, Potsdam, Germany

<sup>4</sup>IMS Health, Frankfurt am Main, Germany

## ABSTRACT

**Background:** The goal of this study was to estimate the prevalence of and risk factors for diagnosed depression in heart failure (HF) patients in German primary care practices.

**Methods:** This study was a retrospective database analysis in Germany utilizing the Disease Analyzer® Database (IMS Health, Germany). The study population included 132,994 patients between 40 and 90 years of age from 1,072 primary care practices. The observation period was between 2004 and 2013. Follow-up lasted up to five years and ended in April 2015. A total of 66,497 HF patients were selected after applying exclusion criteria. The same number of 66,497 controls were chosen and were matched (1:1) to HF patients on the basis of age, sex, health insurance, depression diagnosis in the past, and follow-up duration after index date.

**Results:** HF was a strong risk factor for diagnosed depression ( $p < 0.0001$ ). A total of 10.5% of HF patients and 6.3% of matched controls developed depression after one year of follow-up ( $p < 0.001$ ). Depression was documented in 28.9% of the HF group and 18.2% of the control group after the five-year follow-up ( $p < 0.001$ ). Cancer, dementia, osteoporosis, stroke, and osteoarthritis were associated with a higher risk of developing depression. Male gender and private health insurance were associated with lower risk of depression.

**Conclusions:** The risk of diagnosed depression is significantly increased in patients with HF compared to patients without HF in primary care practices in Germany.

**Key words:** depression, primary care, risk factors, antidepressants

## Introduction

Cardiovascular diseases (CVD) are the leading cause of death in Europe and around the world (Nichols *et al.*, 2014), CVD were the leading cause of death in Germany, comprising 39.7% and a total of 354,493 deaths in 2013 (Debus *et al.*, 2013). Heart failure (HF) is a condition caused by a number of CVD and is primarily exhibited by the elderly (Uemura, 1988; Peeters *et al.*, 2002; Ramsay *et al.*, 2014). Its prevalence is increasing and an estimated 15 million people in Europe are affected by this disease (Ewen *et al.*, 2015).

Epidemiological data show that when considering a steadily aging population and assuming a stable incidence in people over 65 years, a doubling of the incidence of HF is expected compared to the interval 2000 to 2040 (Edelmann, 2015).

HF is characterized by clinical signs of insufficient cardiac activity such as shortness of breath, fatigue, and fluid retention, an increased incidence of arrhythmias and a reduced quality of life and poor prognosis (Ewen *et al.*, 2015). These impairments can be associated with depression (Heßlinger *et al.*, 2002). Notwithstanding, depression symptoms are associated with increased risk for HF in a dose response manner. They can trigger extracardiac events which cause HF, such as neurohormonal stress activity, which regulates blood pressure, heart rate, proinflammatory cytokine, and catecholamine levels (Edelmann, 2015; Ewen *et al.*, 2015).

Correspondence should be addressed to: Prof. Dr Karel Kostev, IMS Health, Epidemiology, Darmstädter Landstraße 1089, 60598 Frankfurt am Main, Germany. Phone: +49 69 6604 4878. Email: [kkostev@de.imshealth.com](mailto:kkostev@de.imshealth.com). Received 7 Jan 2016; revision requested 6 May 2016; revised version received 9 May 2016; accepted 16 May 2016. First published online 16 June 2016.

Further, depression symptoms influence other risk factors for HF, in particular, obesity and reduced physical activity (Gustad *et al.*, 2014).

Despite the high prevalence rates, the individual burden, cost, and negative prognostic impact, depression is often not recognized and treated in patients with HF (Müller-Tasch *et al.*, 2007). Studies concerning the prospective association between depression risk and HF are rare (Gustad *et al.*, 2014) especially in primary care practices. There is a lack of knowledge, specifically relating to the frequency of mental disorders such as depression in patients in primary care practices as well as to how often they are associated with somatic disorders like HF (Pieper *et al.*, 2008). Therefore, the goal of this study was to estimate the prevalence of and risk factors for diagnosed depression in HF patients in German primary care practices.

## Methods

### Database

The Disease Analyzer database (IMS HEALTH) compiles drug prescriptions, diagnoses, basic medical, and demographic data obtained directly and in anonymous format from computer systems used in the practices of general practitioners (Becher *et al.*, 2009). Diagnoses (ICD-10), prescriptions (Anatomical Therapeutic Chemical (ATC) Classification System), and the quality of reported data have been monitored by IMS based on a number of criteria (e.g. completeness of documentation, linkage between diagnoses and prescriptions). In Germany, the sampling methods used for the selection of physicians' practices were appropriate for obtaining a representative database of primary care practices (Becher *et al.*, 2009). Prescription statistics for several drugs were very similar to data available from pharmaceutical prescription reports (Becher *et al.*, 2009). The age groups for given diagnoses in Disease Analyzer were also consistent with those in corresponding disease registries (Becher *et al.*, 2009).

### Study population

This study included patients between 40 and 90 years of age from 1,072 primary care practices who received a first HF diagnosis (ICD 10: I50) during the index period (January 2004 to December 2013). Follow-up lasted up to five years and ended in April 2015. Patients were excluded when they were diagnosed with depression (ICD-10: F32, F33) or received any antidepressant

prescription (ATC: N06A) within 12 months prior to HF diagnosis (index date). A total of 66,497 HF patients were selected after applying these exclusion criteria. Finally, 66,497 controls without HF, depression diagnosis or antidepressant prescriptions within 12 months prior to index date (any random selected visit date) were chosen and matched (1:1) to HF patients by age, sex, type of health insurance (private or statutory), depression diagnosis in the past (more than 12 months prior to index date), and follow-up duration after index date.

### Study outcome

The primary outcome was the diagnosis of depression recorded in the database between the index date and the end of follow-up. Depression diagnoses were based on primary care documentation. Depression diagnoses documented by primary care physicians are mainly confirmed by psychiatrists.

### Statistical analyses

Descriptive statistics were obtained and differences in characteristics of patients (HF vs. controls) were assessed using Wilcoxon tests for paired samples or McNemar's tests. The analyses of depression-free survival were carried out using Kaplan–Meier curves and log-rank tests. Cox proportional hazards models (dependent variable: depression) were used to adjust for confounders. Other chronic conditions which could be associated with depression risk were determined based on primary care diagnoses and included as confounders. They include the following: diabetes mellitus (E10-14), hypertension (I10), dementia (F01, F03, G30), stroke (F63, F64, G45), coronary heart disease (I24, I25), myocardial infarction (I21-23), osteoporosis (M80, M81), cancer (C00-C98), osteoarthritis (M15-19).  $p$ -values < 0.05 were considered as statistically significant. The analyses were carried out using SAS version 9.3.

## Results

### Patient characteristics


Patient characteristics are displayed in Table 1. A total of 132,994 participants were included in both HF and control groups. Mean age was equal to 71.8 years (SD 10.6 years) and 50.3% of patients were men. 6.8% of patients and matched controls had private health insurance coverage. The proportion of patients with prior depression diagnosis (>12 month prior to index date) was 11.3% in both groups. Diabetes,

**Table 1.** Characteristics of heart failure patients and matched controls in German primary care practices

VARIABLES <sup>a</sup>	HF GROUP	CONTROL GROUP	p-VALUE
N	66,497	66,497	
Age (years)	71.8 (10.6)	71.8 (10.6)	1.000
Males (%)	50.3	50.3	1.000
Private health insurance (%)	6.8	6.8	1.000
Follow up time (years)	2.8 (1.7)	2.8 (1.7)	1.000
Depression diagnosis in the past (>12 months prior to index date)	11.3	11.3	1.000
<i>Co-Diagnosis<sup>b</sup> (%):</i>			
Diabetes	38.4	23.7	<0.0001
Hypertension	77.3	57.8	<0.0001
Coronary heart disease	38.7	18.1	<0.0001
Myocardial infarction	6.8	2.3	<0.0001
Stroke	10.2	5.6	<0.0001
Cancer	10.2	7.6	<0.0001
Dementia	7.2	4.6	<0.0001
Osteoarthritis	33.9	23.9	<0.0001
Osteoporosis	12.1	8.5	<0.0001

<sup>a</sup>Data are means (SD) or proportions (%).

<sup>b</sup>Diagnosis prior to index date.



**Figure 1.** Kaplan–Meier curves for time to depression diagnosis in heart failure patients and matched controls.

hypertension, coronary heart disease, myocardial infarction, stroke, cancer, dementia, osteoarthritis, and osteoporosis diagnoses were more frequent in the HF group than in the control group ( $p < 0.001$ ).

### Proportion of patients with depression diagnosis

Kaplan–Meier curves for time to depression diagnosis in HF and control groups are displayed in [Figure 1](#). A total of 10.5% of HF patients and 6.3% of matched controls developed depression after one year of follow-up ( $p < 0.001$ ). Depression diagnoses were presented in 28.9% of the HF group

and 18.2% of the control group after the five-year follow-up ( $p < 0.001$ ).

### Risk factors for depression diagnosis

The results of the multivariate Cox regression model for depression diagnosis in HF patients and matched controls are illustrated in [Table 2](#). HF was a strong risk factor for depression development (HR: 1.56,  $p < 0.0001$ ). As was anticipated, prior depression episodes also increased the risk of renewed depression diagnosis (HR: 2.83,  $p < 0.0001$ ). Furthermore, cancer (HR: 1.25), dementia (HR: 1.24), osteoporosis (HR: 1.17), stroke (HR: 1.16), and osteoarthritis (HR: 1.10)

**Table 2.** Multivariate Cox regression model for depression diagnosis in heart failure patients and matched controls

VARIABLES	HAZARD RATIO (95% CI)	p-VALUE
Heart failure	1.56 (1.52–1.60)	<0.0001
Depression diagnosis in the past	2.83 (2.74–2.92)	<0.0001
Cancer	1.25 (1.20–1.31)	<0.0001
Dementia	1.24 (1.17–1.31)	<0.0001
Osteoporosis	1.17 (1.13–1.22)	<0.0001
Stroke	1.16 (1.10–1.21)	<0.0001
Osteoarthritis	1.10 (1.07–1.13)	<0.0001
Coronary heart disease	1.04 (1.01–1.07)	0.0161
Hypertension	1.01 (0.98–1.04)	0.5086
Diabetes	1.01 (0.98–1.04)	0.6369
Myocardial infarction	1.03 (0.96–1.09)	0.4376
Age (years)	1.00 (1.00–1.00)	0.1236
Male gender	0.72 (0.70–0.74)	<0.0001
Private insurance	0.90 (0.84–0.95)	<0.0001

were associated with a higher risk of developing depression ( $p$ -values < 0.0001). By contrast, male gender (HR: 0.72) and private health insurance (HR = 0.90) were associated with lower risk of depression.

## Discussion

Cardiovascular disorders (including HF) are in general associated with depressive disorders (Bleumink *et al.*, 2004; Pieper *et al.*, 2008; de Hert *et al.*, 2011). In this study, we observed that HF is significantly associated with depression risk. Our results are consistent with previous research exhibiting an increased prevalence of depression among HF patients (Bleumink *et al.*; 2004, Pieper *et al.*, 2008). The results of this study further indicated that the proportion of HF patients with depression continually increased over the five years of follow-up. Polikandrioti *et al.* were also able to show that longer duration of the condition was associated with a higher probability of being depressed (Polikandrioti *et al.*, 2015). This can be attributed to the fact that functional limitations in patients with HF increase with a longer duration and a higher degree of HF severity. This in turn can lead to an increased prevalence of depressive symptoms and depression development (Bleumink *et al.*, 2004).

In accordance with international results, the risk of depression in women is greater than in men (Pieper *et al.*, 2008). Current outcomes from the DEGS study (Study on Adult Health in Germany) showed that women are affected by depression twice as often as men (w: 10.2%; m: 6.1%) (Busch *et al.*, 2013). Our study likewise indicated that

male gender was associated with a lower risk of depression. It is interesting to note that we observed that study subjects with private health insurance coverage have a lower risk of developing depression. Although a correlation with social status likely exists, no information pertaining to this criterion is available to explain the result.

In the present study, a positive association was indicated between depression and the aforementioned chronic conditions. Comorbidities such as cancer, dementia, osteoporosis, stroke, and osteoarthritis are associated with a greater chance of developing depression. These results correspond to prior research. Cancer patients experience a three-fold higher rate of depression than the general population within the first five years of diagnosis (Currier *et al.*, 2014). Depression is also an important precursor to dementia. In this context, dementia was associated with significantly higher rates of depression (Snowden *et al.*, 2015) and depression has been shown to be associated with dementia and cognitive decline (Rapp *et al.*, 2006; Rapp *et al.*, 2011). Increased rates of depression can be observed in patients with osteoporosis. A pathophysiological mediation is also discussed for the relationship between depression and osteoporosis (Pieper *et al.*, 2008). Stroke is a risk factor for the development of depression (Pettersson *et al.*, 2014). Depression is highly prevalent after stroke, and is also associated with the presence of stroke risk factors such as hypertension (Pieper *et al.*, 2008). On the one hand, a bidirectional connection can be established for stroke, since patients who are suffering from a depressive disorder have an increased risk of cerebrovascular events. On the other hand, depressive syndromes after stroke can be frequently observed

(Hellmann-Regen *et al.*, 2014). Osteoarthritis is the most common type of arthritis among older adults. Increased rates of depression can be observed in patients with osteoarthritis (Albrecht, 2014). It is assumed that depression is an indirect consequence in terms of a response to a feared or actual disability by means of a somatic disorder. Finally, the risk of depression increases steadily with the number of comorbid diseases (Pieper *et al.*, 2008).

In general, retrospective primary care database analyses are limited by the degree of completeness of the data on which they are based. The major limitation is related to the diagnoses performed by primary care physicians, as depression cannot be fully diagnosed. Unfortunately, additional data on the depression diagnoses was lacking and in diagnosed patients no information was available regarding the extent to which the diagnoses were made, for example, whether they were made solely on a clinical basis or by means of additional validated questionnaires. Detailed information on the severity of the depression was also lacking. Data on socioeconomic status (e.g. education, income) and lifestyle-related risk factors (e.g. smoking, alcohol, physical activity) were lacking, which is a probable explanation for the relationship between insurance status and depression.

In conclusion, HF was a strong risk factor for depression development. Overall, it should be noted that individuals with depression and HF have shorter life expectancies compared to the general population (Lederbogen *et al.*, 2015). The current findings also indicate that improved detection and treatment of patients with HF and depression is of importance. For this purpose, it is necessary to educate more primary care physicians on how to properly detect the symptom overlap between these two disorders. Sustainable supply concepts are required for an aging society in primary care practices in view of the complex treatment needs of an increasing number of chronically ill and multimorbid patients (Lübeck *et al.*, 2015). Therefore, further research is of high relevance.

### Conflict of interest

None.

### Description of authors' roles

Marcel Konrad co-wrote the article. Jens Bohlken participated in formulating the research questions, co-designed the study, and provided his medical expertise. Michael A Rapp participated in formulating the research questions and provided his

medical expertise. Karel Kostev participated in formulating the research questions, co-designed the study, analyzed the data, and co-wrote the paper.

### Acknowledgments

Professional English language editing services were provided by Claudia Jones, MA, Radford, Virginia, United States.

### References

- Albrecht, K.** (2014). Gender-spezifische Unterschiede der Komorbidität bei rheumatoider Arthritis. *Zeitschrift für Rheumatologie*, 73, 607–614.
- Becher, H., Kostev, K. and Schröder-Bernhardi, D.** (2009). Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmaco-economic studies. *International Journal of Clinical Pharmacology and Therapeutics*, 47, 617–626.
- Bleumink, G. S. et al.** (2004). Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The rotterdam study. *European Heart Journal*, 25, 1614–1619.
- Busch, M., Maske, U., Ryl, L., Schlack, R. and Hapke, U.** (2013). Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*, 56, 733–739.
- Currier, M. B. and Nemeroff, C. B.** (2014). Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. *Annual Review of Medicine*, 65, 203–221.
- De Hert, M. et al.** (2011). Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. *World Psychiatry*, 10, 52–77.
- Debus, E. S. et al.** (2013). Manifestation und prävention der arteriosklerose. *Gefäßchirurgie*, 18, 644–651.
- Edelmann, F.** (2015). Epidemiologie und prognose der herzinsuffizienz. *Herz*, 40, 176–184.
- Ewen, S. and Böhm, M.** (2015). Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms. *European Heart Journal*, 36, 899–901.
- Ewen, S., Mahfoud, F. and Böhm, M.** (2015). Chronische Herzinsuffizienz Aktuelle Leitlinienempfehlungen und neue Erkenntnisse. *Internist*, 56, 791–802.
- Gustad, L. T., Laugsand, L. E., Janszky, I., Dalen, H. and Bjerkeset, O.** (2014). Symptoms of depression and risk of heart failure. The HUNT 2 study. *European Journal of Cardiovascular Nursing*, 16, 861–70.
- Hellmann-Regen, J., Regen, F., Heuser, I., Endres, M. and Otte, C.** (2014). Diagnostik und therapie der post-stroke-depression. *DNP - Der Neurologe und Psychiater*, 15, 61–68.

- Heflinger, B. et al.** (2002). Komorbidität von depressiven Störungen und kardiovaskulären Erkrankungen. *Nervenarzt*, 73, 205–218.
- Lederbogen, F., Schwarz, P., Häfner, S., Schweiger, U., Bohus, M. and Deuschle, M.** (2015). Kardiale und metabolische Risikofaktoren bei schweren psychischen Erkrankungen. *Nervenarzt*, 86, 866–871.
- Lübeck, R., Beyer, M. and Gerlach, F.** (2015). Rationale und stand der hausarztzentrierten Versorgung in Deutschland. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*, 58, 360–366.
- Müller-Tasch, T. et al.** (2007). Psychosomatik der herzinsuffizienz. *Die Medizinische Welt*, 58, 13–16.
- Nichols, M., Townsend, N., Scarborough, P. and Rayner, M.** (2014). Cardiovascular disease in Europe 2014: epidemiological update. *European Heart Journal*, 35, 2950–2959.
- Peeters, A., Mamun, A. A., Willekens, F. and Bonneux, L.** (2002). A cardiovascular life history. A life course analysis of the original framingham heart study cohort. *European Heart Journal*, 23, 458–466.
- Petersson, S., Mathillas, J., Wallin, K., Olofsson, B., Allard, P. and Gustafson, Y.** (2014). Risk factors for depressive disorders in very old age: a population-based cohort study with a 5-year follow-up. *Social Psychiatry and Psychiatric Epidemiology*, 49, 831–839.
- Pieper, L., Schulz, H., Klotsche, J., Eichler, T. and Wittchen, H. U.** (2008). Depression als komorbide Störung in der primärärztlichen Versorgung. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*, 51, 411–421.
- Polikandrioti, M. et al.** (2015). Factors associated with depression and anxiety of hospitalized patients with heart failure. *Hellenic Journal of Cardiology*, 56, 26–35.
- Ramsay, S. E., Whincup, P. H., Papacosta, O., Morris, R. W., Lennon, L. T. and Wannamethee, S. G.** (2014). Inequalities in heart failure in older men: prospective associations between socio- economic measures and heart failure incidence in a 10-year follow-up study. *European Heart Journal*, 35, 442–447.
- Rapp, M. A. et al.** (2006). Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. *Archives of General Psychiatry*, 63, 161–167.
- Rapp, M. A. et al.** (2011). Cognitive decline in patients with dementia as a function of depression. *The American Journal of Geriatric Psychiatry*, 19, 357–363.
- Snowden, M. B. et al.** (2015). Association of dementia and depression. *The American Journal of Geriatric Psychiatry*, 23, 897–905.
- Uemura, K.** (1988). International trends in cardiovascular diseases in the elderly. *European Heart Journal*, 9, 1–8.